



(51) International Patent Classification:

C07D 417/12 (2006.01) A61P 31/20 (2006.01)

A61K 31/42 (2006.01)

(21) International Application Number:

PCT/CN2020/120370

(22) International Filing Date:

12 October 2020 (12.10.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2019/122595

03 December 2019 (03.12.2019) CN

(71) Applicant: GANNEX PHARMA CO., LTD. [CN/CN];

Floor 3, 665 Zhangjiang Road, Shanghai Free Trade Zone, Shanghai 200131 (CN).

(72) Inventors: YANG, Bailing; Floor 3, 665 Zhangjiang

Road, Shanghai Free Trade Zone, Shanghai 200131 (CN).

KRISTJAN, Gudmundsson; Floor 3, 665 Zhangjiang

Road, Shanghai Free Trade Zone, Shanghai 200131 (CN).

DONG, Liuyu; Floor 3, 665 Zhangjiang Road, Shanghai

Free Trade Zone, Shanghai 200131 (CN). CHEN, James;

Floor 3, 665 Zhangjiang Road, Shanghai Free Trade Zone, Shanghai 200131 (CN).

(74) Agent: PANAWELL & PARTNERS, LLC; 1002-1005,

China Life Tower, 16 Chao Yang Men Wai Street, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES





Fig. 2



(57) Abstract: Provided are a method of treating or preventing infection with hepatitis B virus in a human or animal, comprising administering to the human or animal in need thereof a therapeutically effective amount of a phenylisoxazolyl methylene-naphthalene-ether derivative having a structure of formula(I); use of a phenylisoxazolyl methylene-naphthalene-ether derivative having a structure of formula(I) in the preparation of a pharmaceutical composition for anti-hepatitis B virus and a pharmaceutical composition for anti-hepatitis B virus.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*